Nordic Capital proposes $846m acquisition of Advanz Pharma

In a significant move within the pharmaceutical industry, Nordic Capital has made a formal offer to acquire Advanz Pharma, a UK-based specialty pharmaceutical company, for an estimated $846 million in cash. This acquisition, which targets the growing sector of complex medicines, highlights Nordic Capital’s ongoing strategy to bolster its portfolio in the specialty therapeutics market.

Advanz Pharma is well-regarded for its focus on complex therapies, particularly in anti-infectives and endocrinology. The company’s expertise in these areas, combined with its strategic positioning in Europe, made it an attractive target for Nordic Capital, which has been seeking expansion in the specialty medicine space. As per the terms of the deal, Advanz Pharma’s shareholders will receive $17.26 per share in cash, with an additional option to exchange their shares for unlisted shares in BidCo, the Nordic Capital subsidiary set to execute the transaction.

Strategic growth and investment

For both companies, this deal represents a step toward achieving long-term growth objectives. Graeme Duncan, CEO of Advanz Pharma, remarked that the offer underscores the value created by the company’s global workforce. Duncan emphasized that the acquisition will provide substantial capital support and allow Advanz Pharma to leverage Nordic Capital’s deep industry expertise. He expressed confidence that the partnership would accelerate Advanz Pharma’s business expansion, enabling it to reach its future growth targets more effectively.

Raj Shah, Partner and Head of Healthcare at Nordic Capital Advisors, echoed this sentiment, noting that Nordic Capital views the acquisition as an opportunity to further strengthen Advanz Pharma’s platform. He believes that with additional investment and Nordic Capital’s active involvement, Advanz Pharma can accelerate its pipeline of innovative specialty pharmaceutical products. Shah further highlighted that Nordic Capital’s experience in the pharmaceutical sector makes it an ideal partner to help unlock Advanz Pharma’s long-term potential.

The future of Advanz Pharma under Nordic Capital

The transaction, which is set to be executed through a court-sanctioned members’ scheme of arrangement, is expected to provide Advanz Pharma with the necessary resources and expertise to expand its product offerings in the specialty medicines market. Nordic Capital, already one of the most active healthcare investors in Europe and the US, brings significant sector knowledge and capital support, positioning Advanz Pharma to capitalize on emerging opportunities in the pharmaceutical industry.

As Nordic Capital moves forward with the acquisition, both companies are poised to benefit from this strategic partnership, enhancing Advanz Pharma’s capabilities and its potential to drive innovation in complex medicines. This acquisition not only strengthens Nordic Capital’s presence in the pharmaceutical sector but also positions Advanz Pharma to further its ambitions as a leader in specialty therapeutics.